NCT00002027已完成不适用
Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Janssen, LP
- 入组人数
- 60
- 试验地点
- 3
研究概览
简要总结
To evaluate the safety and efficacy of diclazuril capsules compared with placebo capsules as treatment of cryptosporidial related diarrhea in AIDS patients. Treatment efficacy will be based on the drug's clinical results and on its anti-protozoan effects. Safety will be assessed by the occurrence of side effects as reported by patients at their visits and by frequent monitoring of hematology, biochemistries, and urinalysis.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 12 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Patients who require anti-diarrheal medication must have received only one anti-diarrheal medication, loperamide, for at least 7 days prior to study entry. Dose of loperamide cannot be increased during study.
- •Aerosolized pentamidine.
- •Ganciclovir for cytomegalovirus (CMV) retinitis only but patient must be stable at least 4 weeks prior to study entry.
- •Zidovudine (AZT).
- •Nystatin for oropharyngeal infections if not taken within 2 hours of diclazuril.
- •Patients must have:
- •Diagnosis of AIDS that is confirmed HIV positive by Western blot or AIDS defined diagnosis, or CDC defined AIDS. Stool specimens positive for cryptosporidium oocysts.
- •Given written informed consent after the purpose and nature of the study, as well the possible drug-related adverse effects, have been explained.
- •Ability to return for all subsequent applicable visits on days 8, 15, 21, and, if necessary,
- •Prior Medication:
- •Aerosolized pentamidine.
- •Loperamide.
- •Ganciclovir for cytomegalovirus (CMV) retinitis.
排除标准
- •Co-existing Condition:
- •Patients with the following are excluded:
- •Diagnosis of cryptosporidiosis less than 4 weeks prior to study entry, unless patient has been diagnosed with AIDS for more than 4 weeks.
- •Other treatable enteric pathogens including Clostridia must be treated and eradicated prior to study entry.
- •Inability to swallow capsules.
- •Uncontrolled vomiting.
- •Concurrent Medication:
- •Trimethoprim/sulfamethoxazole (Bactrim).
- •Ganciclovir for any other reason except cytomegalovirus (CMV) retinitis.
- •Other antibiotics.
- •Other anti-protozoal drugs.
- •Anti-fungal drugs other than nystatin.
- •Amphotericin B.
- •Other investigational drugs.
- •Patients with the following are excluded:
- •Diagnosis of cryptosporidiosis less than 4 weeks prior to study entry, unless patient has been diagnosed with AIDS for more than 4 weeks.
- •Inability to swallow capsules.
- •Uncontrolled vomiting.
- •Life expectancy of < 28 days.
- •Can not be depended upon to follow the instructions of the investigator.
- •Participation in an investigational study within 15 days of study entry.
- •Prior Medication:
- •Excluded within 15 days of study entry:
- •Another investigational drug or device (except aerosolized pentamidine).
- •Prior Treatment:
- •Excluded within 15 days of study entry:
- •Participation in an investigational study.
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDSHIV InfectionsCryptosporidiosisNCT00002278Janssen, LP
已完成
不适用
Treatment of CryptosporidiosisCryptosporidiosisNCT04103216International Centre for Diarrhoeal Disease Research, Bangladesh64
已完成
2 期
Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic ConjunctivitisAllergic ConjunctivitisNCT01120132Fovea Pharmaceuticals SA716
终止
1 期
Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS PatientsHIV InfectionsCryptosporidiosisNCT00057486National Institute of Allergy and Infectious Diseases (NIAID)2
终止
2 期
D-cycloserine for the Treatment of Chronic, Refractory Low Back PainPainLow Back PainNCT03535688Northwestern University203